BioWorld® - Medical Device Daily

BioWorld Industrial Biotechnology StatReport: Immediate and Comprehensive Industry Information
HISTORY: Founded in 1923
Established in 1940
Acquired ActivX Biosciences Inc. (2/05)
STOCK-FINANCIAL HISTORY: Listed on the Tokyo Stock Exchange
SUBSIDIARIES/DIVISIONS: Kyobundo Co. Ltd.
Bistner Co. Ltd.
Toyo Pharmar Co. Ltd.
Dr. Program Co. Ltd.
ActivX Biosciences Inc.
Kyorin USA. Inc.
Kyorin Europe GmbH
Nisshin Kyorin Pharmaceutical Co. Ltd.
Nippon Rika Co. Ltd.
SUBSIDIARY OF: Kyorin Co. Ltd.
BUSINESS STRATEGY: Manufacture and sell prescription medicines and quasi-drugs, diagnostics
and industrial chemicals
Build alliances that will capitalize on external resources, allowing the
company to further contribute to better the health of people throughout the
world
Invest management resources in specific therapeutic fields for drug
discovery and marketing
AGREEMENTS: Name Products Content of Agreement Date
MediciNova Inc. development and
commercialization of
MN-001 (except Japan,
China Taiwan and
South Korea)
licensing agreement
Novartis AG KRP-203 global development
and
commercialization
licensing agreement
2/06
RESEARCH & DEVELOPMENT: Drug discovery operations are centered on three therapeutic fields:
Infectious diseases, immunological/allergic and metabolic diseases
PRODUCTS ON MARKET: Gatiflo® tablets
Kipres® tablets
Mucodyne®
Ketas® capsules
Baccidal® tablets
Aplace®
Pentasa® tablets
Rocaltrol® capsules
Bestron® for ear and nose
Kyowa Hakko Kogyo Co. Ltd.
1-6-1 Otemachi, Chiyoda-ku
Tokyo 100, Japan
Phone: +81 3-3282-0007; Fax: +81 3-3284-1968
Web: www.kyowa.co.jp/eng; E-mail: info@kyowa.co.jp
KEY PERSONNEL: Dr. Yuzuru Matsuda; President and CEO
Yoshito Imai; Sr. Exec. Managing Officer and President, Pharmaceuticals
Business Unit
Yukinobu Kotani; Sr. Exec. Managing Officer and President, Bio-Chemicals
Business Unit
EMPLOYEES: 5,800 employees
Copyright ©2006 AHC Media ® 210